May Adjournment
Debate between Julian Lewis and Jeremy Lefroy(6 years ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Jeremy Lefroy (Stafford) (Con)
I am most grateful to follow the speech of my distinguished colleague, my hon. Friend the Member for Gainsborough (Sir Edward Leigh). I very much agree with him on a lot of areas, but I shall start with a point where I might pose a little challenge. I believe we wish, as a country, to be strong on defence. I absolutely agree with him on that and think that what my right hon. Friend the Member for Sevenoaks (Sir Michael Fallon) has said about a minimum of 2.5%—and possibly even more—is right. I am very proud that Stafford is host to three signals regiments and the tactical supply wing of the Royal Air Force. If we are to be a global Britain, punching above our weight by maintaining a proper diplomatic representation around the world, which is vital as we leave the European Union, and at the same time we are to ensure that our citizens have high-quality public services, be they in respect of law and order, health or social care, we cannot be an absolute low tax economy. The two things do not add up. If we look at the percentage of GDP that we spend on our public services and compare that with what happens in France, which has a similar global profile to the UK, we see that our figure is much, much less.
At this point I wish to raise the issue of our health service. I declare an interest, in that I am married to a doctor, and I am the father of a doctor and the brother of a doctor.
Jeremy Lefroy
My right hon. Friend may very well ask!
If we look at the World Health Organisation’s report on people’s perceptions of access to good quality healthcare in 2013, under a Conservative-led coalition Government, I am glad to say, we find that 82% of France’s population and 85% of Germany’s felt they had access to good quality healthcare, whereas in the UK the figure was 96%. For all its faults, and there are many, as I know personally from my constituency experience, our system is held in high regard and it provides almost everybody—96% is not 100%—with access to high-quality healthcare.
Lariam
Debate between Julian Lewis and Jeremy Lefroy(7 years, 6 months ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Dr Lewis
That is probably the single strongest point that one could make in the course of this entire debate. Particularly in the macho military environment—I use that term in a non-sexist way—people are unlikely to disclose mental troubles in their past, meaning that either they may take a drug that is inappropriate for them or they may throw it away, rendering themselves vulnerable to contracting malaria.
Jeremy Lefroy
Did the Committee have any idea why there is such a particular emphasis on Lariam when other drugs are available, such as doxycycline or Malarone, that many of us take whenever we go to countries affected? The emphasis on Lariam seems to me extraordinary. I absolutely applaud my right hon. Friend’s point about the importance of encouraging Roche to continue its research in this area; we do not want it put off. Roche has been excellent in its clarity about what Lariam is about and what precautions need to be taken.
Dr Lewis
Other Committee members may correct me, but I have a feeling that we never quite got to the bottom of why the MOD is so fixated on that particular drug. What I am about to say is sheer speculation, but it could have something to do with the relative cost of different types of drug, or with concern about compensation claims. If the drug were given up completely, it might be easier to bring claims on that basis: “You don’t prescribe this drug at all now, so therefore you were wrong ever to have prescribed it.”
We sought to give the MOD a bit of wriggle room, for want of a better term, by saying that all we wanted it to do was designate Lariam as a drug of last resort. I do not see why it should not do that. It is obviously a drug of last resort, because the MOD accepts the fact that it should now be issued only under the most strictly defined conditions. What is that if not making it a drug of last resort? So why does the MOD not say so?
Similarly, there has been reluctance to acknowledge the experience of other countries. The MOD asserted that Lariam was
“considered by US CDC”—
the Centers for Disease Control and Prevention, which is the US equivalent of Public Health England—
“to be equally suitable (with an individual clinical assessment) as each of the other drugs”.
However, Dr Remington Nevin—one of the two doctors to whom we owe a great deal of gratitude for their consistent campaigning on this issue and for the evidence they brought to the Committee—described that as a “misinterpretation of CDC’s position”. The section entitled “Special Considerations for US Military Deployments” in chapter 8 of the CDC’s publication “Yellow Book” states:
“The military should be considered a special population with demographics, destinations, and needs that may differ from those of civilian travelers.”
In respect of the use of Lariam in other states’ armed forces, Dr Nevin argued that
“many of our Western allies have all but abandoned the use of the drug”,
and that the US and Australian military use it only for
“those rare service members who cannot tolerate…two safer and equally effective alternatives”.
That is why we made the point that Lariam should really be used only for such people, because we are not convinced that there is any geographical area where some other drug could not be used.
Dr Nevin also referred to the US Army Special Operations Command having taken the
“very wise step of banning it altogether”.
He said that the decision by the US military was made
“primarily on clinical grounds”
and was intended to
“decrease the risk of negative drug-related side-effects”.
The MOD’s response commits merely to updating the information held on the use by our allies of Lariam and other antimalarial drugs, including the extent to which Lariam is used and the circumstances in which it is supplied. It still does not appear to accept that its policy on Lariam is increasingly out of step with that of our allies.
We have made considerable progress by focusing on the terrible situation in which a drug designed for very specific issuing to very specific people after a very specific interview was doled out en masse as a routine prophylactic to our service personnel who were about to go to malaria-infested areas. That really was a scandal, and it would be another scandal if it ever happened again.
Transparency in UK Company Supply Chains (Eradication of Slavery) Bill
Debate between Julian Lewis and Jeremy Lefroy(11 years, 6 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Dr Julian Lewis (New Forest East) (Con)
I begin by congratulating the hon. Member for Linlithgow and East Falkirk (Michael Connarty) on his speech and on taking the Bill forward. I am delighted and proud to be one of the 11 sponsors from five parties, including no fewer than three colleagues who are all named Jim—I am not quite sure of the significance, but I felt that it was worth placing that on the record.
I was first recruited to this admirable cause by the hon. Member for Slough (Fiona Mactaggart) when she brought in a ten-minute rule Bill along the same lines, and it was then taken up by the hon. Member for Linlithgow and East Falkirk in his excellent Bill before us today. I know that he, like me, will be disappointed if it does not proceed to Committee, but it has been given an airing today, as he rightly said, and I am sure that we are all grateful to the Government for having made certain that that would happen.
There was some confusion over the question of human trafficking in relation to the Bill. Human trafficking is certainly one of the concerns covered, but it is neither the Bill’s exclusive focus, nor even its main focus. The main focus of the Bill, as became apparent in the hon. Gentleman’s speech, was brought out at yesterday evening’s reception, which I was pleased to attend. We heard some horrifying tales about what actually goes on overseas in the unsupervised chain of production for many products we see on supermarket shelves, often without the knowledge of not only consumers, but the companies selling the goods. It is therefore also in the interests of the companies and their reputations that they should make an effort to investigate the chain of production for the products they sell so that no one would be tempted to go around marking them on their shelves as having been contaminated by the ruthless exploitation of child labour or that of other impoverished people.
As the hon. Gentleman said, the Bill has a light touch. It would affect only very large companies, companies that have the resources to carry out the sorts of examinations and checks that would assure them and their consumers that the goods being sold had not been created as a result of an unendurable chain of human suffering. I think that I am right in saying that BP is an example of a major company that, although very tough-minded, has nevertheless seen it as appropriate to adopt such measures. If BP can adopt such measures, that sets a good example for other large companies to do likewise.
Dr Lewis
I will not give way, for a reason I am just about to explain.
While talking of setting good examples, I would like to say that there are times for long speeches and times for short speeches. This is a time for short speeches. I look to hon. Members on the Back Benches and on both Front Benches to follow my good example and make short speeches so that this worthy Bill can proceed as it should to Committee.